SonoThera raised an oversubscribed $125 million in a Series B financing to advance ultrasound-mediated delivery of genetic medicines toward clinical testing. The funding round, led by Vida Ventures with participation from major strategic and financial investors including Otsuka and Illumina Ventures, will support Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease programs in the clinic. SonoThera’s platform pairs ultrasound-mediated delivery technology (RIPPLE) with engineered payload delivery (PORE), which the company says is designed to address gene-therapy bottlenecks including delivery limits, immune responses, and the ability to redose. The company expects to begin its first DMD clinical trial in 2027. The financing strengthens the competitive landscape for non-viral, locally targeted and potentially redosable gene-delivery approaches, where clinical differentiation will likely hinge on biodistribution, immunogenicity, and repeat dosing feasibility.